Evidence map›Paper›PMID 34170911›Full record

ArticlePloS one2021

Frequency, timing and risk factors for primary maternal cytomegalovirus infection during pregnancy in Quebec.

Safari Joseph Balegamire, Christian Renaud, Benoît Mâsse, Kate Zinszer, Soren Gantt, Yves Giguere, Jean-Claude Forest, Isabelle Boucoiran

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Article
  5. Prenatal Screening for CMV Primary Infection: A Cost-Utility Model.BJOG : an international journal of obstetrics and gynaecology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. An Overview of Cytomegalovirus Infection in Pregnancy.Diagnostics (Basel, Switzerland) · 2022
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Safari Joseph BalegamireDepartment of Social and Preventive Medicine, École de Santé Publique de Université de Montréal, Montreal, QC, Canada.ORCID 0000-0001-9657-3791
Christian RenaudWomen and Children's Infectious Diseases Center, CHU Sainte-Justine Research Center, Montreal, Canada.
Benoît MâsseDepartment of Social and Preventive Medicine, École de Santé Publique de Université de Montréal, Montreal, QC, Canada.
Kate ZinszerDepartment of Social and Preventive Medicine, École de Santé Publique de Université de Montréal, Montreal, QC, Canada.
Soren GanttWomen and Children's Infectious Diseases Center, CHU Sainte-Justine Research Center, Montreal, Canada.
Yves GiguereCHU de Québec-Université Laval Research Center, Quebec City, Canada.
Jean-Claude ForestCHU de Québec-Université Laval Research Center, Quebec City, Canada.
Isabelle BoucoiranDepartment of Social and Preventive Medicine, École de Santé Publique de Université de Montréal, Montreal, QC, Canada.
Centre Hospitalier Universitaire Sainte-Justine · CAUniversité Laval · CAUniversité de Montréal · CA

Funding

CIHR 386200
6 · The paper itself

Abstract

introductionMaternal Cytomegalovirus (CMV) infection in the first trimester (T1) of pregnancy is a public health concern, as it increases the risk of severe neurodevelopmental outcomes associated with congenital infection compared to infections occurring later during pregnancy.

objectivesTo determine CMV seroprevalence in T1 of pregnancy, its trend, risk factors and the incidence rate of primary infection during pregnancy.

methodsUsing the biobank of the prospective cohort "Grossesse en Santé de Québec" collected between April 2005 and March 2010 at the Québec-Laval Hospital, Québec, Canada, maternal CMV serology was determined using Abbott Architect Chemiluminescence microparticle immunoassays for immunoglobulin G(IgG), immunoglobulin M(IgM) titration and IgG avidity testing. Changepoint detection analysis was used to assess temporal trends. Risk factors associated with seropositivity were determined by multivariable logistic regression.

resultsCMV seroprevalence in T1 of pregnancy was 23.4% (965/4111, 95% CI, 22.1-24.7%). The incidence rate for CMV primary infection during pregnancy was 1.8 (95% CI, 1.2-2.6) per 100 person-years. No changepoint was identified in the maternal CMV-seroprevalence trend. Multivariable analyses showed that T1 maternal CMV seropositivity was associated with having one child OR 1.3 (95% CI, 1.10-1.73) or two or more children OR 1.5 (95%CI, 1.1-2.1), ethnicity other than Caucasian OR 2.1 (95% CI, 1.1-3.8) and country of birth other than Canada and the USA OR 2.8 (95% CI, 1.5-4.9).

conclusionsIn this cohort, maternal seroprevalence in T1 of pregnancy and seroconversion rate were low. This information and identified risk factors could help guide the development and implementation of preventive actions and evidence-based health policies to prevent CMV infection during pregnancy.

Indexed as

AdolescentAdultAntibodies, ViralCytomegalovirusCytomegalovirus InfectionsFemaleFetal DiseasesHumansImmunoglobulin GImmunoglobulin MInfectious Disease Transmission, VerticalMaleParturitionPregnancyPregnancy Complications, InfectiousPregnancy Trimester, FirstAntibodies, ViralImmunoglobulin GImmunoglobulin M

Identifiers

PMID34170911
PMCPMC8232530
OpenAlexW3176029908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.